EUVIMEDEUVIMED entdecken
Crossref

Mycophenolate mofetil may be an alternative for maintenance therapy of Behçet syndrome uveitis: a single-center retrospective analysis

Didar Ucar, Sinem Nihal Esatoglu, Emir Cerme, Bilge Batu-Oto, Vedat Hamuryudan, Emire Seyahi, Melike Melikoglu, Izzet Fresko, Yılmaz Ozyazgan, Gulen Hatemi

Rheumatology International · 2023

DOI: 10.1007/s00296-023-05420-4 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Rheumatology International, 2023. Verfasst von Didar Ucar und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Cerrahpaşa Medical Faculty Istanbul University-Cerrahpaşa, Istanbul, Turkey. Hauptthemen laut MEDLINE: Behcet Syndrome, Uveitis. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 32 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Experience with mycophenolate in uveitis due to Behçet syndrome (BS) is limited. Twelve patients with panuveitis or posterior uveitis who were started mycophenolate were included. Data on demographic characteristics, therapies, ocular attacks, and adverse events were extracted from patient charts. Seven patients with BS uveitis were prescribed mycophenolate for remission induction, of which 6 were refractory/intolerant to conventional immunosuppressives. Mycophenolate was combined with anti-TNFs in 3 patients, resulting in no further ocular attacks. Mycophenolate had to be stopped in the fourth patient due to adverse events. The remaining 3 patients continued to have ocular attacks and were switched to other agents without any drop in visual acuity. Among the 5 patients who were prescribed mycophenolate for maintenance, 2 were relapse free, but 3 experienced ocular attacks. One patient had an exacerbation of mucocutaneous lesions, and 2 experienced adverse events. Mycophenolate monotherapy may not be adequate for remission induction of refractory BS uveitis, but it can be a safe and effective alternative when combined with a biologic agent. It may also be an option for maintenance therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Behcet SyndromeUveitisHumansMycophenolic AcidRetrospective StudiesImmunosuppressive Agents

Stichwörter der Autor:innen

Behçet syndromeEye involvementMycophenolateTreatmentUveitis

Substanzen

Mycophenolic AcidImmunosuppressive Agents

Autor:innen und Institutionen

  • Department of Ophthalmology, Cerrahpaşa Medical Faculty Istanbul University-Cerrahpaşa, Istanbul, Turkey.
  • Behçet's Disease Research Center, Istanbul University-Cerrahpaşa, Istanbul, Turkey.
  • Behçet's Disease Research Center, Istanbul University-Cerrahpaşa, Istanbul, Turkey. nihalesatoglu@gmail.com.
  • Division of Rheumatology, Department of Internal Medicine, Cerrahpaşa Medical Faculty Istanbul University-Cerrahpaşa, Istanbul, Turkey. nihalesatoglu@gmail.com.
  • Division of Rheumatology, Department of Internal Medicine, Cerrahpaşa Medical Faculty Istanbul University-Cerrahpaşa, Istanbul, Turkey.

Zitieren

APA

Ucar, D., Esatoglu, S. N., Cerme, E., Batu-Oto, B., Hamuryudan, V., Seyahi, E., Melikoglu, M., Fresko, I., Ozyazgan, Y., & Hatemi, G. (2023). Mycophenolate mofetil may be an alternative for maintenance therapy of Behçet syndrome uveitis: a single-center retrospective analysis. Rheumatology International. https://doi.org/10.1007/s00296-023-05420-4

Vancouver

Ucar D, Esatoglu SN, Cerme E, Batu-Oto B, Hamuryudan V, Seyahi E, et al. Mycophenolate mofetil may be an alternative for maintenance therapy of Behçet syndrome uveitis: a single-center retrospective analysis. Rheumatology International. 2023. doi:10.1007/s00296-023-05420-4

BibTeX
@article{Ucar2023,
  author = {Ucar, Didar and Esatoglu, Sinem Nihal and Cerme, Emir and Batu-Oto, Bilge and Hamuryudan, Vedat and Seyahi, Emire and Melikoglu, Melike and Fresko, Izzet and Ozyazgan, Yılmaz and Hatemi, Gulen},
  title = {Mycophenolate mofetil may be an alternative for maintenance therapy of Behçet syndrome uveitis: a single-center retrospective analysis},
  journal = {Rheumatology International},
  year = {2023},
  doi = {10.1007/s00296-023-05420-4}
}
Kostenlos starten →